Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

75.86
+0.20000.26%
Volume:437.35K
Turnover:33.00M
Market Cap:12.53B
PE:-31.87
High:76.00
Open:75.15
Low:75.04
Close:75.66
52wk High:86.74
52wk Low:23.95
Shares:165.19M
Float Shares:164.00M
Volume Ratio:0.68
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3800
EPS(LYR):-2.3812
ROE:-70.80%
ROA:-7.31%
PB:25.62
PE(LYR):-31.86

Loading ...

Director Lynne Parshall Reports Sale of Ionis Pharmaceuticals Common Shares

Reuters
·
Feb 14

Press Release: Ionis to hold fourth quarter and full year 2025 financial results webcast

Dow Jones
·
Feb 11

Ionis Pharmaceuticals CEO Brett P. Monia Reports Sale of Common Shares

Reuters
·
Feb 11

Ionis Pharmaceuticals (IONS) Valuation Check As Dawnzera Approval And Other Milestones Support Growth Prospects

Simply Wall St.
·
Feb 08

Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 07

Ionis Pharmaceuticals price target raised to $87 from $77 at Piper Sandler

TIPRANKS
·
Feb 06

Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Disposal of Common Shares

Reuters
·
Feb 03

Ionis Pharmaceuticals EVP Chief Business Officer Joseph Baroldi Reports Sale of Common Shares

Reuters
·
Feb 03

Has Ionis Pharmaceuticals (IONS) Run Too Far After Its 152% One Year Surge?

Simply Wall St.
·
Jan 30

Ionis Pharmaceuticals assumed with an Overweight at Barclays

TIPRANKS
·
Jan 28

Why Ionis Pharmaceuticals (IONS) Is Up 5.2% After EU Approval of DAWNZERA for HAE Prevention

Simply Wall St.
·
Jan 24

Ionis Pharmaceuticals EVP Shannon L. Devers Reports Sale of Common Shares

Reuters
·
Jan 24

Ionis Pharmaceuticals announces European Commission approval for Dawnzera

TIPRANKS
·
Jan 21

BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)

Reuters
·
Jan 21

EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention

Reuters
·
Jan 21

Dawnzera™ (Donidalorsen) Approved in the European Union for Hereditary Angioedema (Hae)

THOMSON REUTERS
·
Jan 21

Ionis Pharmaceuticals Inc - Eligible for Milestone Payment of $15 Mln and Tiered Royalties of up to 30% on Net Product Sales

THOMSON REUTERS
·
Jan 21

Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Sale of Common Shares

Reuters
·
Jan 21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 19

Analysts Are Bullish on Top Healthcare Stocks: Healthequity (HQY), Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 19